{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:58:45Z","timestamp":1777640325882,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Canadian Fabry Disease Initiative Research Consortium","award":["Canadian Fabry Disease Initiative Research Consortium"],"award-info":[{"award-number":["Canadian Fabry Disease Initiative Research Consortium"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fabry disease (FD) is an X-linked disorder caused by deleterious variants in\n                      <jats:italic>GLA.<\/jats:italic>\n                      Cardiovascular disease (CVD) causes premature mortality in FD. Hope for aspirin (acetylsalicylic acid, ASA) to reduce CVD risks in FD as primary prevention may have been tempered by the 2018 ARRIVE, ASCEND, and ASPREE clinical trials. It is unclear how new ASA guidance applies to FD patients, who have a high rate of young-onset, small vessel stroke compared with the general population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Longitudinal data spanning 2007\u20132023 from patients in the Canadian Fabry Disease Initiative (CFDI) were analyzed retrospectively. Incident stroke and transient ischemic attack (TIA), other CVD events, FD-specific risk factors, and ASA\/antiplatelet (\u201cASA\/AP\u201d) prescription before and after 2018 were compared between groups who never had an event (\u201cprimary prevention group\u201d) to those who had incident stroke\/TIA during the study. Stroke\/TIA rates were compared within CFDI by sex and\n                      <jats:italic>GLA<\/jats:italic>\n                      variant severity, and in the CFDI compared to Canadian statistics by sex. Ten-year atherosclerotic CVD (ASCVD) risk was calculated using the 2013 ACC\/AHA risk calculator. ASA\/AP prescription rate was compared before and after 2018.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 641 patients, 57 had an incident stroke\/TIA during the study, and 193 with complete data remained in the primary prevention group. Stroke\/TIA rates were significantly higher among male patients (0.026 events per patient-year) than females (0.0098 events per patient-year), and higher among patients with severe\n                      <jats:italic>GLA<\/jats:italic>\n                      variants (males: 0.031 events per patient-year, females: 0.0096 events per patient-year) compared to those with attenuated variants (males: 0.011 events per patient-year, females: 0.0088 events per patient-year). No patients under 60 years at their incident stroke\/TIA had high (\u2265\u200910%) calculated 10-year ASCVD risk. Fewer patients were prescribed ASA\/AP for primary prevention after 2018.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was a high incidence of stroke\/TIA in the younger CFDI cohort compared to the general Canadian population, despite low levels of traditional vascular risk factors as represented in 10-year estimated ASCVD risk. Primary prevention use of ASA has declined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04098-0","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:17:45Z","timestamp":1762521465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors, stroke rates and aspirin prescribing trends in the Canadian Fabry disease initiative cohort"],"prefix":"10.1186","volume":"20","author":[{"given":"Emilie T.","family":"Th\u00e9berge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Selvage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaye M.","family":"LeMoine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Robichaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darwin F.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Sirrs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the CFDI investigators group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"1","key":"4098_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","volume":"17","author":"DA Laney","year":"2008","unstructured":"Laney DA, Fernhoff PM. Diagnosis of Fabry disease via analysis of family history. J Genet Couns. 2008;17(1):79\u201383.","journal-title":"J Genet Couns"},{"key":"4098_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"4098_CR3","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genet Med. 2009;11(11):790\u20136.","journal-title":"Genet Med"},{"issue":"12","key":"4098_CR4","first-page":"e12083","volume":"12","author":"V Mishra","year":"2020","unstructured":"Mishra V, Banerjee A, Gandhi AB, Kaleem I, Alexander J, Hisbulla M, Kannichamy V, Valaiyaduppu Subas S, Hamid P. Stroke and Fabry disease: A review of literature. Cureus. 2020;12(12):e12083.","journal-title":"Cureus"},{"issue":"3","key":"4098_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","volume":"40","author":"K Sims","year":"2009","unstructured":"Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry. Stroke. 2009;40(3):788\u201394.","journal-title":"Stroke"},{"issue":"24","key":"4098_CR6","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1001\/jama.296.24.2939","volume":"296","author":"R Carandang","year":"2006","unstructured":"Carandang R, Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Kannel WB, Wolf PA. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA. 2006;296(24):2939\u201346.","journal-title":"JAMA"},{"issue":"11","key":"4098_CR7","first-page":"e19358","volume":"13","author":"JF Ortiz","year":"2021","unstructured":"Ortiz JF, Parwani J, Millhouse PW, Eissa-Garc\u00e9s A, Hassen G, Cuenca VD, Alzamora IM, Khurana M, Herrera-Bucheli D, Altamimi A, et al. Prevalence of Fabry disease in patients with cryptogenic strokes: A systematic review. Cureus. 2021;13(11):e19358.","journal-title":"Cureus"},{"issue":"12","key":"4098_CR8","doi-asserted-by":"publisher","first-page":"E302","DOI":"10.1503\/cmaj.191599","volume":"192","author":"T Wein","year":"2020","unstructured":"Wein T, Lindsay MP, Gladstone DJ, Poppe A, Bell A, Casaubon LK, Foley N, Coutts SB, Cox J, Douketis J, et al. Canadian stroke best practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events. CMAJ. 2020;192(12):E302\u201311.","journal-title":"CMAJ"},{"issue":"9678","key":"4098_CR9","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849\u201360.","journal-title":"Lancet"},{"issue":"16","key":"4098_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529\u201339.","journal-title":"N Engl J Med"},{"issue":"10152","key":"4098_CR11","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","volume":"392","author":"JM Gaziano","year":"2018","unstructured":"Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036\u201346.","journal-title":"Lancet"},{"issue":"16","key":"4098_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"16","key":"4098_CR13","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/jama.2022.4983","volume":"327","author":"KW Davidson","year":"2022","unstructured":"US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, Coker TR, Davis EM, Donahue KE, Ja\u00e9n CR, et al. Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement. JAMA. 2022;327(16):1577\u201384.","journal-title":"JAMA"},{"key":"4098_CR14","unstructured":"Government of Canada. Stroke in Canada: Highlights from the Canadian Chronic Disease Surveillance System. 2019 [Accessed 2024 Feb. 2]. Available from https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/stroke-canada-fact-sheet.html"},{"issue":"25 Suppl 2","key":"4098_CR15","first-page":"S49","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O\u2019Donnell CJ, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of Cardiology\/American heart association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S49\u201373.","journal-title":"Circulation"},{"key":"4098_CR16","doi-asserted-by":"crossref","unstructured":"Yaghi S, Raz E, Yang D, Cutting S, Mac Grory B, Elkind MS, de Havenon A. Lacunar stroke: mechanisms and therapeutic implications. J Neurol Neurosurg Psychiatry. 2021. jnnp-2021-326308.","DOI":"10.1136\/jnnp-2021-326308"},{"issue":"10","key":"4098_CR17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/jamaneurol.2018.1073","volume":"75","author":"RW Regenhardt","year":"2018","unstructured":"Regenhardt RW, Das AS, Lo EH, Caplan LR. Advances in Understanding the pathophysiology of lacunar stroke: A review. JAMA Neurol. 2018;75(10):1273\u201381.","journal-title":"JAMA Neurol"},{"issue":"12","key":"4098_CR18","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2169\/internalmedicine.6420-20","volume":"60","author":"J Sawada","year":"2021","unstructured":"Sawada J, Nakagawa N, Kano K, Saito T, Katayama T, Sawada T, Momosaki K, Nakamura K, Hasebe N. Characteristics of neurological symptoms in adult Japanese patients with Fabry disease. Intern Med. 2021;60(12):1819\u201326.","journal-title":"Intern Med"},{"issue":"5","key":"4098_CR19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","volume":"251","author":"MJ Hilz","year":"2004","unstructured":"Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004;251(5):564\u201370.","journal-title":"J Neurol"},{"issue":"2","key":"4098_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","volume":"99","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Twickler TB, Aerts JMFG, Linthorst GE, Wijburg FA, Hollak CEM. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010;99(2):99\u2013108.","journal-title":"Mol Genet Metab"},{"issue":"15","key":"4098_CR21","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jacc.2023.07.025","volume":"82","author":"A Greco","year":"2023","unstructured":"Greco A, Occhipinti G, Giacoppo D, Agnello F, Laudani C, Spagnolo M, Mauro MS, Rochira C, Finocchiaro S, Mazzone PM, et al. Antithrombotic therapy for primary and secondary prevention of ischemic stroke: JACC State-of-the-Art review. J Am Coll Cardiol. 2023;82(15):1538\u201357.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4098_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00228-022-03413-z","volume":"79","author":"X Hou","year":"2023","unstructured":"Hou X, Cen K, Cui Y, Zhang Y, Feng X. Antiplatelet therapy for secondary prevention of lacunar stroke: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2023;79(1):63\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"4098_CR23","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1161\/STROKEAHA.114.008422","volume":"46","author":"CS Kwok","year":"2015","unstructured":"Kwok CS, Shoamanesh A, Copley HC, Myint PK, Loke YK, Benavente OR. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke. 2015;46(4):1014\u201323.","journal-title":"Stroke"},{"key":"4098_CR24","doi-asserted-by":"crossref","unstructured":"Burlina AP, Al-Shaar L, Germain DP, Banikazemi M, Ponce E, Crespo A, Lawson V, Politei J. Reduced incidence of stroke in patients with Fabry disease treated with agalsidase beta: a matched analysis from the Fabry Registry [conference abstract]. Mol Genet Metab. 2025;144(2).","DOI":"10.1016\/j.ymgme.2024.108669"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04098-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04098-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04098-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:17:47Z","timestamp":1762521467000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04098-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4098"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04098-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used aggregate deidentified data of patients consented into the Canadian Fabry Disease Initiative registry, such that additional re-consent for publication was not required. Data analysis by E.T. was conducted under the approval of the University of British Columbia Clinical Research Ethics Board application #H17-00574.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have received funding for research (unrestricted), clinical trials, speaker fees, or advisory boards related to Fabry disease from Takeda, Amicus, Idorsia, Chiesi, or Sanofi Genzyme.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"567"}}